The 2014-2015 outbreak of Ebola virus disease is the largest epidemic to date in 
terms of the number of cases, deaths, and affected areas. In October 2015, no 
antiviral agents had proven antiviral efficacy in patients. However, in 
September 2014, the World Health Organization inventoried and has since 
regularly updated a list of potential drug candidates with demonstrated 
antiviral efficacy in in vitro or animal models. This includes agents belonging 
to various therapeutic classes, namely direct antiviral agents (favipiravir and 
BCX4430), a combination of antibodies (ZMapp), type I interferons, RNA 
interference-based drugs (TKM-Ebola and AVI-7537), and anticoagulant drugs 
(rNAPc2). Here, we review the pharmacokinetic and pharmacodynamic information 
presently available for these drugs, using data obtained in healthy volunteers 
for pharmacokinetics and data obtained in human clinical trials or animal models 
for pharmacodynamics. Future studies evaluating these drugs in clinical trials 
are critical to confirm their efficacy in humans, propose appropriate doses, and 
evaluate the possibility of treatment combinations.